生物医药行业：ILLUMINA 被我国列入不可靠实体清单，国产测序仪有望提升市占率

Investment Rating - The industry investment rating is "Outperform the Market" [4][41]. Core Insights - Illumina has been placed on China's unreliable entity list, which may allow domestic sequencing companies like BGI Genomics to increase their market share [4]. - The report suggests focusing on themes of "innovation," "going global," "equipment upgrades," and "consumer recovery" within the biopharmaceutical sector [5]. Summary by Sections Industry Overview - The Chinese Ministry of Commerce announced the inclusion of Illumina in the unreliable entity list, which could lead to restrictions on its operations in China. This situation presents an opportunity for domestic competitors like BGI Genomics to capture a larger share of the market [4]. Investment Strategy - The report recommends attention to the following themes: - Innovation: Focus on innovative drugs with global competitiveness, suggesting companies like Dongcheng Pharmaceutical and Jiutian Pharmaceutical [6]. - Going Global: Identifying long-term opportunities in overseas markets, with companies like Mindray Medical and Sinopharm [6]. - Equipment Upgrades: Anticipating support for medical equipment updates, recommending companies like Mindray Medical and United Imaging [6]. - Consumer Recovery: Expecting a rebound in sectors like ophthalmology and aesthetic medicine, with companies like Pure Eye Hospital and Haohai Biological [6]. Key Companies to Watch - Yuan Dong Bio: Expected short-term performance boost from product collection and innovative pipeline [8]. - Jianyou Co.: High growth in overseas formulations and potential rebound in domestic collection [8]. - Ascentage Pharma: Strategic partnerships and promising drug pipeline for global expansion [8]. - Kexing Pharmaceutical: Anticipated significant growth in overseas sales and innovative drug pipeline [8]. - Jingxin Pharmaceutical: Expected revenue growth driven by product adjustments and new drug approvals [8]. - Kunming Pharmaceutical: Benefiting from national procurement policies and expected performance acceleration [9].